BN Business News
Add your company to Business Communicator →

Zdrowie i gospodarka · 12/08/2026

NIH-Owned Invention Available for License: Drug-Regulatable, Inducible Expression of Membrane-Bound Interleukin 12 (DRIM-IL-12) for Use in Adoptive Cell Therapy

The National Cancer Institute (NCI) is seeking partners to advance a novel, tightly regulated cytokine platform that enhances anti-tumor efficacy in adoptive cell therapy, while improving safety, and is available for license.

Source: Federal Register — Health and Human ServicesOpen original release →